Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man

S. F. Slovin, G. Ragupathi, S. Adluri, G. Ungers, K. Terry, S. Kim, M. Spassova, W. G. Bornmann, M. Fazzari, L. Dantis, K. Olkiewicz, K. O. Lloyd, P. O. Livingston, S. J. Danishefsky, H. I. Scher

Research output: Contribution to journalArticle

228 Citations (Scopus)

Abstract

The complex carbohydrate molecule globo H hexasaccharide has been synthesized, conjugated to keyhole limpet hemocyanin, and administered with the immunologic adjuvant QS-21 as a vaccine for patients with prostate cancer who have relapsed after primary therapies such as radiation or surgery. Globo H is one of several candidate antigens present on prostate cancer cells that can serve as targets for immune recognition and treatment strategies. The vaccine, given as five subcutaneous vaccinations over 26 weeks, has been shown to be safe and capable of inducing specific high-titer IgM antibodies against globo H. Its immunogenicity was confirmed in prostate cancer patients with a broad range of stages and tumor burdens. Observations of several patients who had evidence of disease relapse restricted to a rising biochemical marker, prostate-specific antigen (PSA), indicated that a treatment effect could occur within 3 months after completion of the vaccine therapy. This effect was manifested as a decline of the slope of the log of PSA concentration vs. time plot after treatment compared with values before treatment. Five patients continue to have stable PSA slope profiles in the absence of any radiographic evidence of disease for more than 2 years. The concept of using PSA slope profiles in assessing early treatment effects in biological therapies such as vaccines awaits further validation in phase II and III trials. The use of a variety of lesser known candidate glycoprotein and carbohydrate antigens in prostate cancer serves as a focus for the development of a multivalent vaccine of the treatment of relapsed prostate cancer in patients with minimal tumor burden.

Original languageEnglish (US)
Pages (from-to)5710-5715
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume96
Issue number10
DOIs
StatePublished - May 11 1999
Externally publishedYes

Fingerprint

Cancer Vaccines
Carbohydrates
Prostatic Neoplasms
Prostate-Specific Antigen
Vaccines
Tumor Burden
Therapeutics
Antigens
Immunologic Adjuvants
Active Immunotherapy
Biological Therapy
Globo-H
Immunoglobulin M
Glycoproteins
Vaccination
Biomarkers
Radiation
Recurrence
Antibodies

ASJC Scopus subject areas

  • General

Cite this

Carbohydrate vaccines in cancer : Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. / Slovin, S. F.; Ragupathi, G.; Adluri, S.; Ungers, G.; Terry, K.; Kim, S.; Spassova, M.; Bornmann, W. G.; Fazzari, M.; Dantis, L.; Olkiewicz, K.; Lloyd, K. O.; Livingston, P. O.; Danishefsky, S. J.; Scher, H. I.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 96, No. 10, 11.05.1999, p. 5710-5715.

Research output: Contribution to journalArticle

Slovin, SF, Ragupathi, G, Adluri, S, Ungers, G, Terry, K, Kim, S, Spassova, M, Bornmann, WG, Fazzari, M, Dantis, L, Olkiewicz, K, Lloyd, KO, Livingston, PO, Danishefsky, SJ & Scher, HI 1999, 'Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man', Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 10, pp. 5710-5715. https://doi.org/10.1073/pnas.96.10.5710
Slovin, S. F. ; Ragupathi, G. ; Adluri, S. ; Ungers, G. ; Terry, K. ; Kim, S. ; Spassova, M. ; Bornmann, W. G. ; Fazzari, M. ; Dantis, L. ; Olkiewicz, K. ; Lloyd, K. O. ; Livingston, P. O. ; Danishefsky, S. J. ; Scher, H. I. / Carbohydrate vaccines in cancer : Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. In: Proceedings of the National Academy of Sciences of the United States of America. 1999 ; Vol. 96, No. 10. pp. 5710-5715.
@article{a2a0197c71ee4732bf12df2132d92435,
title = "Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man",
abstract = "The complex carbohydrate molecule globo H hexasaccharide has been synthesized, conjugated to keyhole limpet hemocyanin, and administered with the immunologic adjuvant QS-21 as a vaccine for patients with prostate cancer who have relapsed after primary therapies such as radiation or surgery. Globo H is one of several candidate antigens present on prostate cancer cells that can serve as targets for immune recognition and treatment strategies. The vaccine, given as five subcutaneous vaccinations over 26 weeks, has been shown to be safe and capable of inducing specific high-titer IgM antibodies against globo H. Its immunogenicity was confirmed in prostate cancer patients with a broad range of stages and tumor burdens. Observations of several patients who had evidence of disease relapse restricted to a rising biochemical marker, prostate-specific antigen (PSA), indicated that a treatment effect could occur within 3 months after completion of the vaccine therapy. This effect was manifested as a decline of the slope of the log of PSA concentration vs. time plot after treatment compared with values before treatment. Five patients continue to have stable PSA slope profiles in the absence of any radiographic evidence of disease for more than 2 years. The concept of using PSA slope profiles in assessing early treatment effects in biological therapies such as vaccines awaits further validation in phase II and III trials. The use of a variety of lesser known candidate glycoprotein and carbohydrate antigens in prostate cancer serves as a focus for the development of a multivalent vaccine of the treatment of relapsed prostate cancer in patients with minimal tumor burden.",
author = "Slovin, {S. F.} and G. Ragupathi and S. Adluri and G. Ungers and K. Terry and S. Kim and M. Spassova and Bornmann, {W. G.} and M. Fazzari and L. Dantis and K. Olkiewicz and Lloyd, {K. O.} and Livingston, {P. O.} and Danishefsky, {S. J.} and Scher, {H. I.}",
year = "1999",
month = "5",
day = "11",
doi = "10.1073/pnas.96.10.5710",
language = "English (US)",
volume = "96",
pages = "5710--5715",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "10",

}

TY - JOUR

T1 - Carbohydrate vaccines in cancer

T2 - Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man

AU - Slovin, S. F.

AU - Ragupathi, G.

AU - Adluri, S.

AU - Ungers, G.

AU - Terry, K.

AU - Kim, S.

AU - Spassova, M.

AU - Bornmann, W. G.

AU - Fazzari, M.

AU - Dantis, L.

AU - Olkiewicz, K.

AU - Lloyd, K. O.

AU - Livingston, P. O.

AU - Danishefsky, S. J.

AU - Scher, H. I.

PY - 1999/5/11

Y1 - 1999/5/11

N2 - The complex carbohydrate molecule globo H hexasaccharide has been synthesized, conjugated to keyhole limpet hemocyanin, and administered with the immunologic adjuvant QS-21 as a vaccine for patients with prostate cancer who have relapsed after primary therapies such as radiation or surgery. Globo H is one of several candidate antigens present on prostate cancer cells that can serve as targets for immune recognition and treatment strategies. The vaccine, given as five subcutaneous vaccinations over 26 weeks, has been shown to be safe and capable of inducing specific high-titer IgM antibodies against globo H. Its immunogenicity was confirmed in prostate cancer patients with a broad range of stages and tumor burdens. Observations of several patients who had evidence of disease relapse restricted to a rising biochemical marker, prostate-specific antigen (PSA), indicated that a treatment effect could occur within 3 months after completion of the vaccine therapy. This effect was manifested as a decline of the slope of the log of PSA concentration vs. time plot after treatment compared with values before treatment. Five patients continue to have stable PSA slope profiles in the absence of any radiographic evidence of disease for more than 2 years. The concept of using PSA slope profiles in assessing early treatment effects in biological therapies such as vaccines awaits further validation in phase II and III trials. The use of a variety of lesser known candidate glycoprotein and carbohydrate antigens in prostate cancer serves as a focus for the development of a multivalent vaccine of the treatment of relapsed prostate cancer in patients with minimal tumor burden.

AB - The complex carbohydrate molecule globo H hexasaccharide has been synthesized, conjugated to keyhole limpet hemocyanin, and administered with the immunologic adjuvant QS-21 as a vaccine for patients with prostate cancer who have relapsed after primary therapies such as radiation or surgery. Globo H is one of several candidate antigens present on prostate cancer cells that can serve as targets for immune recognition and treatment strategies. The vaccine, given as five subcutaneous vaccinations over 26 weeks, has been shown to be safe and capable of inducing specific high-titer IgM antibodies against globo H. Its immunogenicity was confirmed in prostate cancer patients with a broad range of stages and tumor burdens. Observations of several patients who had evidence of disease relapse restricted to a rising biochemical marker, prostate-specific antigen (PSA), indicated that a treatment effect could occur within 3 months after completion of the vaccine therapy. This effect was manifested as a decline of the slope of the log of PSA concentration vs. time plot after treatment compared with values before treatment. Five patients continue to have stable PSA slope profiles in the absence of any radiographic evidence of disease for more than 2 years. The concept of using PSA slope profiles in assessing early treatment effects in biological therapies such as vaccines awaits further validation in phase II and III trials. The use of a variety of lesser known candidate glycoprotein and carbohydrate antigens in prostate cancer serves as a focus for the development of a multivalent vaccine of the treatment of relapsed prostate cancer in patients with minimal tumor burden.

UR - http://www.scopus.com/inward/record.url?scp=13044253477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13044253477&partnerID=8YFLogxK

U2 - 10.1073/pnas.96.10.5710

DO - 10.1073/pnas.96.10.5710

M3 - Article

C2 - 10318949

AN - SCOPUS:13044253477

VL - 96

SP - 5710

EP - 5715

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 10

ER -